The paper deals with the results of an investigation of the release of selected amino acids (histidine, tryptophan, tyrosine) from model suspensions prepared by co-precipitation with zinc chloride. It has been proven that the influence of the Zn(II)/amino acid molar ratio on dissolution profiles of the tested amino acids and dissolution half-life (t 1/2 ) of histidine or tryptophan is significant. The amount of amino acid in the dispersed phase (supporting dose) is a determinant of the amino acid release profile. There is a minimal supporting dose (30.0 μmol of histidine or 17.4 μmol of tryptophan) that provides release of similar amounts of amino acid (4.1-4.6 μmol of histidine or 8.7-9.9 μmol of tryptophan) after the same time intervals. The tyrosine release profiles follow first order kinetics since the supporting dose (0.9-11.2 μmol) is limited by the tyrosine low solubility in water.
salt. AAs-histidine (His), tryptophan (Trp) and tyrosine (Tyr) served as model substances. Influence of the Zn(II)/AA molar ratio on the release of AA from suspensions was investigated. Due to their aromatic structure, the tested AA could be easily determined by the spectrophotometric method. -1 NaOH solution provided the optimal pH value for AA binding in the dispersed phase and was determined on the basis of preliminary experiments. Total volume was adjusted to 10.0 mL with distilled water. The suspensions were stirred using a magnetic stirrer at 500 rpm for 25 min. The suspensions were then left at room temperature for 1 h.
Optical microscopy of AA-Zn(II) suspensions
Optical microscope (MT 4000 Series Meiji Techno Co. LTP, Japan) was used to study the particle size of the suspension. A drop of undiluted formulation was viewed using total magnification of 100 or 400×.
Characterization of AA-Zn(II) suspensions
The suspensions (10 mL) were centrifuged for 10 minutes at 4000 rpm. The pH values, concentrations of AA and Zn(II) were then determined in the supernatant. The amounts of AA (supporting dose) and Zn(II) in the dispersed phase were calculated as the difference between the initial amount and those determined in the supernatant. The precipitate was intended for use in the in vitro release study of AA.
In vitro release study of AA from suspensions
The precipitate was re-suspended in 10 mL of 0.9 % NaCl solution and stirred with a magnetic stirrer at 500 rpm for 30 min. The suspension was subjected to centrifugation at 4000 rpm for 10 min and the amount of dissolved AA was determined in the supernatant.
The precipitate was re-suspended in 10 ml of fresh 0.9 % NaCl solution and the procedure was repeated. The study was carried out until dissolution of 95 % of the AA supporting dose or for 5 h.
Spectrophotometric determination of AA
Absorbance (x) was measured in 1 cm quartz cuvettes using a CE 3021 UV-Vis spectrometer (Cecil, UK). The photometric accuracy of the spectrophotometer was ± 0.005. AA concentration (y) was calculated on the basis of regression equations (His y = 0.0387x + 0.0053 R 2 > 0.999; Trp y = 0.1758x + 0.0087 R 2 > 0.999; Tyr y = 0.0466x + 0.0256 R 2 > 0.999). Absorbance was measured at wavelengths (λ max ) at which maximum absorbance was observed (λ max (His) = 211.0 nm, λ max (Trp) = 218.5 nm, λ max (Tyr) = 222.5 nm).
Complexometric determination of Zn(II)
Zn(II) was determined by complexometric titration using 0.05 mol L -1 EDTA in the presence of Eriochrome Black T in pH 10 ammonia buffer until the initially violet solution turned blue (Polish Pharmacopeia VI).
Determination of pH values
pH values were measured using a Microcomputer pH-meter CP-315 (POCH, Poland). The electrode was calibrated using 0.05 mol L -1 sodium phosphate buffer solution purchased in Chempur, Poland.
Analysis of AA release data
The release kinetics of AA from the suspensions were elucidated by fitting the release data to kinetic models (first order or zero order) (Table I ) and by comparison of the squared correlation coefficients R 2 values. AA dissolution half-lives (t 1/2 , h) were calculated according to the kinetics with the higher value of R 2 ( Table I) .
Data analysis
The results were presented as the mean value (x ± SD) of 5 experiments and were analyzed using Excel (Microsoft Office) and Statistica 10 (Statsoft) computer programs. The influence of Zn(II)/AA on selected parameters was analyzed using ANOVA and Tukey's 
post-hoc test. The influence of the Zn(II)/AA molar ratio on dissolution profiles of AA was analyzed using ANOVA. The level of statistical significance was p < 0.05.
Determination and evaluation of theoretical AA release profiles
Theoretical AA release profiles were determined on the basis of the plot of the amount of AA released after the first 0.5 h against the amount of AA in the dispersed phase (AA supporting dose). Theoretical amount of AA released after the 0.5 h interval (y) corresponded to the remaining amount of AA (new supporting dose) (x). Similarity of theoretical and empirical AA release profiles was tested by means of relative error δ x , which was calculated by the equation:
, where j is a number of time points, n is a total number of time points, x j is amount of AA released during 0.5 h at time point j (%) (curve 1) and y j is amount of AA released during 0.5 h at time point j (%) (curve 2).
Dissolution profiles were also compared using a model independent method. Fit factors-f 1 ' (difference factor) and f 2 (similarity factor) were calculated by the equations:
where j is a number of time points, n is a total number of time points, R j and T j are cumulative percent of AA dissolved at each time point (curve 1 and curve 2, respectively).
According to the FDA guide for industry, f 1 ' values up to 15 (0-15) and f 2 values greater than 50 (50-100) ensure sameness or equivalence of the two curves (11) .
RESULTS AND DISCUSSION
Properties of the obtained suspensions (pH value, AA and Zn(II) concentration in the dispersed phase and particle size) are summarized in Table II. Parenteral suspensions with protein-peptide hormones should be in the pH range 7.10-7.50. For research purposes and in order to obtain suspensions with the optimal amount of AA bound in the dispersed phase, the extended pH range was applied. Percent of AA bound in the dispersed phase was 57. (Table II) . Suspensions with 30-57 μmol His and 17-83 μmol Trp in the dispersed phase released similar amounts of AA after 0.5 h (4.1-4.6 μmol His and 8.7-9.9 μmol Trp). Suspensions with smaller amounts of AA in the dispersed phase released smaller amounts of AA after 0.5 h. However, the amount of Tyr released after 0.5 h was directly proportional to the amount of Tyr in the dispersed phase (Fig. 1) . Fig. 2 shows AA release profiles and Fig. 3 shows cumulative AA release profiles. Theoretical AA release profiles (calculated from Fig. 1 ) are also marked (Figs. 2 and 3) .
Relative error values δ x < 20 % and fit factor values (f 1 ' < 15 and f 2 > 50) confirmed the similarity of theoretical and empirical AA release profiles. This indicates that the amount of AA in the dispersed phase (maintenance dose) is the factor determining the AA release profile.
ANOVA showed a significant effect of the Zn(II)/AA molar ratio on the cumulative AA release (%) (p < 0.05).
Kinetic analysis of the AA release data (first order and zero order R 2 squared coefficients, t 1/2 (h) and Korsmeyer-Peppas diffusion exponent n values) is given in Table III . The data calculated from the theoretical dissolution profiles are also summarized in Table III  (in parentheses) .
Release kinetics (zero order or first order) was determined on the basis of the R 2 correlation coefficients and Korsmeyer-Peppas diffusion exponent n values (Table III) . Korsmeyer-Peppas diffusion exponent n value equal to 1.0 is indicative of zero order kinetics (Fig. 1) . Release of AA from the Zn(II)/His 15:1 or Zn(II)/ Trp 1.5:1 suspensions followed neither zero order nor first order kinetics (Table III) . The release of His from Zn(II)/His 15:1 was incomplete (61.5 %) (Fig. 3a) . Release of Trp from the Zn(II)/Trp 1.5:1 suspension followed initially zero order kinetics (64.85 % of Trp supporting dose) as the amount of Trp in the dispersed phase was greater than 17.4 μmol during the first 2 h. Trp release was then reduced as the amount of Trp in the dispersed phase dropped below 17.4 μmol (Fig. 2c) . In other cases, the release of AA from His-Zn(II), Trp-Zn(II) or Tyr-Zn(II) suspensions followed first order kinetics (R 2 > 0.900 (Table III) . No release of Tyr following zero order kinetics was obtained because of the small amount of Tyr in the dispersed phase (0.9-11.2 μmol). Obtaining Tyr-Zn(II) suspensions with higher Tyr supporting dose was limited due to the low solubility of Tyr in water.
Release kinetics (zero order or first order) could be also determined on the basis of the theoretical AA release profiles; calculated R 2 values are summarized in Table III. ANOVA showed a significant effect of the Zn(II)/AA molar ratio on the KorsmeyerPeppas diffusion exponent n value in the case of all three AA (p < 0.05). However, Zn(II)/ His 1. The t 1/2 values calculated according to the kinetics with higher R 2 value are summarized in Table III . ANOVA showed a significant effect (p < 0.05) of the Zn(II)/AA molar ratio on the t 1/2 value (His-Zn(II) or Trp-Zn(II) suspensions). However, Zn(II)/AA 1.5:1 and 15:1 Zn(II)/AA suspensions had the same t 1/2 value (His, p = 0.31; Trp, p = 0.72). Zn(II)/Tyr effect on the t 1/2 value was not significant (p = 0.08).
CONCLUSIONS
The amount of amino acid in the dispersed phase (supporting dose) is the determining factor of the release profile. There is a minimal supporting dose that provides the release of similar amounts of amino acid after the same time intervals (zero order kinetics).
Amino acid solubility in water is a limiting factor for obtaining suspensions with a supporting dose high enough to provide a release profile following zero order kinetics and sustained release.
